Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Tumor-associated antigens (TAAs) are selectively or aberrantly expressed on cancer cells and represent critical targets for oncology research and therapeutic development. Recombinant TAA proteins provide essential tools for target validation, antibody discovery, and functional characterization across diverse cancer indications.
Our Tumor-Associated Antigen recombinant protein solutions are designed to support oncology-focused research programs, with structurally defined extracellular constructs, multiple species options, and application-oriented formats tailored for antibody and cell therapy development.
Unlike broadly expressed receptors or signaling molecules, tumor-associated antigens require high specificity, structural accuracy, and assay compatibility. This portfolio is developed to support the earliest stages of oncology research through to advanced therapeutic evaluation.
This portfolio covers a wide spectrum of well-established and emerging tumor-associated antigens across solid tumors and hematologic malignancies.
Representative targets include:
Multiple species options, including human, mouse, cynomolgus monkey, and rhesus macaque, support translational and preclinical model development.
Tumor antigen recognition is highly dependent on epitope presentation and protein conformation. Recombinant proteins are designed to preserve relevant extracellular regions while supporting experimental flexibility.
Available formats include:
Domain-specific constructs are available for select antigens to support epitope-focused studies.
To ensure native-like folding and post-translational modifications, the majority of tumor-associated antigens are produced using mammalian expression systems. Selected intracellular or truncated antigens are expressed in bacterial systems where appropriate.
Expression strategies are chosen based on antigen complexity, glycosylation requirements, and downstream application needs.
Oncology research demands consistent and reproducible reagents. Each recombinant tumor antigen is produced under standardized quality control processes designed to support sensitive binding and functional assays.
Key quality considerations include:
This Tumor-Associated Antigen recombinant protein portfolio is supplied for research use only and is designed to integrate seamlessly into oncology discovery and translational research pipelines. Broad antigen coverage, flexible construct formats, and application-driven design enable reliable support from early target discovery through advanced therapeutic development.
For target availability, construct options, species coverage, or custom project support, please explore individual product pages or contact our technical support team.
| Cat.No. | Product Name | Price |
|---|---|---|
| RP00001 | Recombinant Cynomolgus HER2 (C-Fc) | Inquiry |
| RP00004 | Recombinant Human CD27 (C-Fc-6His) | Inquiry |
| RP00011 | Recombinant Human HER2 (C-Fc) | Inquiry |
| RP00024 | Recombinant Human GPC3 (C-Fc) | Inquiry |
| RP00036 | Recombinant Human FOLR1 (C-6His) | Inquiry |
| RP00040 | Recombinant Human HER2 (C-6His) | Inquiry |
| RP00043 | Recombinant Human CD47 (C-6His) | Inquiry |
| RP00045 | Recombinant Human GPC3 (C-6His) | Inquiry |
| RP00056 | Recombinant Mouse DLL3 (C-6His) | Inquiry |
| RP00061 | Biotinylated Human FOLR1 (C-Fc-Avi) | Inquiry |
| RP00067 | Recombinant Human DLL3 (C-6His) | Inquiry |
| RP00068 | Recombinant Mouse DLL3 (C-6His) | Inquiry |
| RP00070 | Recombinant Human CLEC12A (N-Fc) | Inquiry |
| RP00071 | Recombinant Human CLEC12A (N-6His) | Inquiry |
| RP00078 | Recombinant Human CLEC12A (N-Fc) | Inquiry |
Copyright © Creative Biogene. All rights reserved.